Two CFTR mutations within codon 970 differently impact on the chloride channel functionality.

Area of Science:

• Molecular Biology
• Genetics
• Pharmacology

Background:

• Cystic fibrosis (CF) pharmacotherapy effectiveness varies with CFTR mutation type.
• The p.Gly970Asp mutation's response to CFTR modulators was unknown, despite a similar mutation's varied response.
• Understanding mutation-specific effects is crucial for personalized CF treatment.

Purpose of the Study:

• To investigate the functional impact of the p.Gly970Asp CFTR mutation.
• To determine the potential benefit of CFTR pharmacotherapy for a patient with the p.Gly970Asp mutation.
• To assess the role of mRNA splicing in CFTR mutation response.

Main Methods:

• Complementary DNA transfection to assess CFTR function.
• Messenger RNA (mRNA) analysis to evaluate splicing defects.
• Pharmacological treatment of patient-derived nasal epithelial cells.

Main Results:

• Both p.Gly970Asp and p.Gly970Arg mutations result in defective CFTR function.
• The p.Gly970Asp mutation does not impair mRNA splicing, unlike p.Gly970Arg.
• Nasal epithelial cells from the p.Gly970Asp patient showed improved CFTR function with pharmacological treatment.

Conclusions:

• CFTR pharmacotherapy can be effective for the p.Gly970Asp mutation.
• mRNA splicing analysis is critical for predicting CFTR pharmacotherapy response.
• Personalized medicine approaches require detailed characterization of mutation effects at the molecular level.